Thursday, August 8, 2013

Healio: Phase 3 trial assessing therapy for post-liver transplant HCV initiated

Phase 3 trial assessing therapy for post-liver transplant HCV initiated
August 8, 2013

Biotest AG has initiated treatment in a phase 3 clinical trial in North America of a therapy for patients who require liver transplantation because of hepatitis C infection, according to a press release.

The phase 3 trial will assess the efficacy, safety and pharmacokinetics of 10% hepatitis C hyperimmune globulin Civacir (Biotest AG) among patients with HCV undergoing liver transplantation, and will include 90 patients across the United States and Canada. The first patient began treatment after liver transplantation and several weeks of therapy with virostatics.

Treatment is intended to prevent HCV recurrence following liver transplant, as antiviral therapies can lead to tolerability and safety concerns in this patient population. It would be the first treatment approved for this indication, according to the release. The medication has received Orphan Drug designation in the United States and European Union, allowing for market exclusivity for 7 and 10 years, respectively, upon approval.

Exercise may reduce metabolic syndrome among liver transplant recipients
August 8, 2013
Liver transplant recipients were less likely to develop metabolic syndrome when reporting regular and more intense exercise in a recent study.

In a cross-sectional analysis, researchers evaluated 204 liver transplant recipients who had undergone transplantation more than 3 months before study enrollment (median 53.5 months). Height, weight, waist circumference and blood pressure were assessed, and patients reported the duration, frequency per week and metabolic equivalents (METS) of their physical activity.
Full Story »

Afinitor fails to meet survival endpoint for liver cancer indication
August 7, 2013

A global phase 3 study of everolimus as a treatment for patients with advanced liver cancer did not improve survival among users compared with placebo recipients, according to a press release.
Full Story »

No comments:

Post a Comment